Changes in cytokine profile during local IL-2 therapy in cancer patients

Anticancer Research

Volumn 26, Issue 3 A, 2006, Pages 2037-2047

  Tomova, Radosveta ^a   Pomakov, Javor ^a   Jacobs, John J L ^b   Adjarov, Dimcho ^a   Popova, Svetlana ^a   Altankova, Iskra ^a   Den Otter, Willem ^b   Krastev, Zachary ^a  

^a UNIVERSITY HOSPITAL ST IVAN RILSKI   (Bulgaria)

^b Faculty of Veterinary Medicine   (Netherlands)

Author keywords

Cytokines; IL 10; IL 2 therapy; IL 5

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; ASCITES; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMETRY; DIGESTIVE SYSTEM CANCER; DRUG ACTIVITY; DRUG INHIBITION; DRUG MECHANISM; FEMALE; HUMAN; MALE; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; INTERFERON TYPE II; INTERLEUKIN-2; INTERLEUKINS; MALE; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33745590423     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Balemans LTM, Mattijssen V, Steerenberg PA, Van Driel BE, De Mulder PHM and Den Otter W: Locoregional therapy with polyethyleneglycol-modified interleukin-2 of an intradermally growing hepatocellular carcinoma in guinea pigs induces T-cell-mediated antitumour activity. Cancer Immunol Immunother 37: 7, 1993.
2. Kusnierczyk H, Pajtasz-Piasecka E, Koten J-W, Bijleveld C, Krawczyk K and Den Otter W: Further development of local IL-2 therapy of cancer: multiple versus single IL-2 treatment of transplanted murine colon carcinoma. Cancer Immunol Immunother 53: 445-452, 2004.
3. Den Otter W, Hill FWG, Klein WR, Koten JW, Steerenberg PA, De Mulder PHM, Rhode C, Faber JAJ, Ruitenberg EJ and Rutten VPMG: Therapy of bovine ocular squamous cell carcinoma with local doses of interleukin-2: 67% complete regressions after 20 months of follow-up. Cancer Immunol Immunother 41: 10-14, 1995.
4. Spoormakers TJ, Klein WR, Jacobs JJ, Van Den Ingh TS, Koten JW and Den Otter W: Comparison of the efficacy of local treatment of equine sarcoids with IL-2 or cisplatin/IL-2. Cancer Immunol Immunother 52: 179-184, 2003.
5. Krastev Z, Koltchakov V, Tomov B and Koten JW: Non melanoma and non renal cell carcinoma malignancies treated with interleukin 2. Hepato-Gastroenterology 50: 1006-1016, 2003.
6. Den Otter W, Battermann JJ, Bernsen MR, Cadee JA, Dobrowolski Z, Everse LA, Fiszer-Maliszewska L, Gavhumende R, De Groot JW, De Groot K, Hennink WE, Hill FWG, Jurgenliemp-Schulz I, Klein WR, Koten JW, Maas RA, Steerenberg P, Stewart R and Zembala M: Local low-dose IL-2 therapy. Hepato-Gastroenterology 46: 1280-1286, 1999.
7. Bernsen MR, Tang JW, Everse LA, Koten JW and Den Otter W: IL-2 therapy: potential advantages of locoregional versus systemic administration. Cancer Treat Rev 25: 73-82, 1999.
8. Lissoni P, Barni S, Ardizzoia A, Paolorossi F, Tisi E, Crispino S and Tancini G: Intracavitary administration of IL-2 as palliative therapy for neoplastic effusions. Tumori 7: 118-120, 1992.
9. Krastev Z, Koltchakov V, Popov D, Alexiev A, Koten JW and Den Otter W: A case of hepatocellular carcinoma (HCC): treatment with local application of alcohol and interleukin-2 (IL-2). Hepatogastroenterology 50: 1647-1649, 2003.
10. Krastev Z, Koltchakov V, Vladov N, Popov D, Milev A, Koten JW and Den Otter W: A mesothelioma that is sensitive to locally applied IL-2. Cancer Immunol Immunother 50: 226-227, 2001.
11. Den Otter W, Dobrowolski Z, Bugajski A, Papla B, Van der Meijden APM, Koten JW, Boon TA, Siedlar M and Zembala M: Intravesical interleukin-2 in T1 papillary bladder carcinoma: regression of marker lesion in 8 out of 10 patients. J Urol 159: 1183-1186, 1998.
12. Jacobs JJL, Hordijk GJ, Jurgenliemk-Schulz IM, Terhaard CHJ, Koten JW, Battermann JJ and Den Otter W: Treatment of stage III-IV nasopharyngeal carcinomas by external beam irradiation and local low dose of IL-2. Cancer Immunol Immunother 54: 792-798, 2005.
13. Huland E, Heinzer H and Huland H: Treatment of pulmonary metastatic renal-cell carcinoma in 116 patients using inhaled interleukin-2 (IL-2). Anticancer Res 19: 2679-2683, 1999.
14. Lucey DR, Clerici M and Shearer GM: Type 1 and type 2 cytokine dysregulation in human infections, neoplastic, and inflammatory diseases. Clin Microbiol Rev 9: 532-562, 1996.
15. Hsu DH, Moore KW and Spits H: Differential effects of IL-4 and IL-10 on IL-2 induced INFγ synthesis and lymphokine-activated killer activity. Int Immunol 4: 563-569, 1992.
16. Fiorentino DF, Zlotnik A, Viera P, Mosmann TR, Howard M, Moore KW and O'Garra A: IL-10 inhibits cytokine production by activated macrophages. J Immunol 146: 3444-3451, 1991.
17. Wakkach A, Cottrez F and Groux H: Can interleukin-10 be used as a true immunoregulatory cytokine? Eur Cytokine Netw 11: 153-160, 2000.
18. Hernandez-Pando R and Rook GAW: The role of TNF-alpha in T-cell inflammation depends on the TH1/TH2 cytokine balance. Immunology 82: 591-595, 1994.
19. Nakayama H, Kitayama J, Muto T and Nagawa H: Characterization of intracellular cytokine profile of CD4+ T-cells in peripheral blood and tumor-draining lymph nodes of patients with gastrointestinal cancer. Japanese Journal of Clinical Oncology 30: 301-305, 2000.
20. Goto S, Sato M, Kaneho R, Itoh M, Sato S and Tahenechi S: Analysis of TH1 and TH2 cytokine production by peripheral blood mononuclear cells as a parameter of immunological dysfunction in advanced cancer patients. Cancer Immunol. Immonother 48: 435-442, 1999.
21. Pellegrini P, Berghella AM, Del Beato T, Cicia S, Adorno D and Casciani CU: Disregulation of TH1 and TH2 subsets of CD4+ T-cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression. Cancer Immunol Immonother 42: 1-8, 1996.
22. Roussel E, Gingras MC, Grimm EA, Bruner JM and Moser RP: Predominance of a type 2 intratumoral immune response in fresh tumor-infiltrating lymphocytes from human gliomas. Clin Exp Immunol 105: 344-352, 1996.
23. Lauerova L, Dusek L, Simickova M, Kocak I, Vagundova M, Zaloudik J and Kovarik J: Malignant melanoma associates with TH1/TH2 imbalance that coincides with disease progression and immunotherapy response. Neoplasma 49: 159-166, 2002.
24. Parmiani G: An explanation of the variable clinical response to IL-2 and LAK cells. Immunology Today 11: 113-115, 1990.
25. Mantovani G, Maccio A, Pisano M, Versace R, Lai P, Esu S, Massa E, Ghiani M, Dessi D, Melis GB and Del Giacco GS: Tumor-associated lympho-monocytes from neoplastic effusions are immunologically defective in comparison with patient autologous PBMCs but are capable of releasing high amounts of various cytokines. Int J Cancer 71: 724-731, 1997.
26. Chapman PB, Kolitz JE, Hakes TB, Gabrilore JL, Welte K, Merluzzi VJ, Engert A, Bradley EC, Konrad M and Mertelsmann R: A phase I trial of intraperitoneal recombinant interleukin 2 in patients with ovarian carcinoma. Investig New Drugs 6: 179-188, 1988.
27. Jacobs JJL, Sparendam D and Den Otter W: Local interleukin 2 therapy is most effective against cancer when injected intratumourally. Cancer Immunol Immunother 54: 647-654, 2005.
28. Blay JY, Farrot MC, Negrier S, Combaret V, Chouaib S, Mercatello A, Kaemmerlen P, Franks CR and Philip T: Correlation between clinical response to interleukin 2 therapy and sustained production of TNF-alpha. Cancer Res 50: 2371-2374, 1990.
29. Deehan DJ, Heys SD, Simpson W, Herriot R, Broom J and Eremin O: Correlation of serum cytokine and acute phase levels with alterations in weight and serum albumin in patients receiving immunotherapy with recombinant IL-2. Clin Exp Immunol 95: 366-372, 1994.
30. Chouaib S, Bertoglio J, Blay JY, Marchiol-Fournigault C and Fradelizi D: Generation of lymphokine-activated killer cells: synergy between tumour necrosis factor and interleukin 2. Proc Natl Acad Sci USA 85: 6875-6879, 1988.
31. Blay JY, Bertoglio J, Fradelizi D and Chouaib S: Functional interactions of IL-2 and TNF in the differentiation of LGL into LAK effectors. Int J Cancer 44: 598-604, 1989.
32. Maas RA, Dullens HF and Den Otter W: Mechanisms of tumor regression induced by low doses of interleukin-2. In Vivo 5: 637-641, 1991.
33. Boccoli G, Masciulli R, Ruggeri EM, Carlini P, Giannella G, Montesoro E, Mastroberardino G, Isacchi G, Testa U and Calabresi F: Adoptive immunotherapy of human cancer: the cytokine cascade and monocyte activation following high-dose IL-2 bolus treatment. Cancer Res 50: 5795-5800, 1990.
34. Grimm EA, Smid CM, Lee JJ, Tseng CH, Eton O and Buzaid AC: Unexpected cytokines in serum of malignant melanoma patients during sequential biochemotherapy. Clin Cancer Res 6: 3895-3903, 2000.
35. Bonig H, Laws HJ, Wundes A, Verheyen J, Hannen M, Kim YM, Banning U, Nurnberger W and Korholz D: In vivo cytokine responses to interleukin-2 immunotherapy after autologous stem cell transplantation in children with solid tumors. Bone Marrow Transplant 26: 91-96, 2000.
36. Freedman RS, Gibbons JA, Giedlin M, Kudelka AP, Kavanagh JJ, Edwards CL, Carrasco CH, Nash MA and Platsoucas CD: Immunopharmacology and cytokine production of a low-dose schedule of intraperitoneally administered human recombinant interleukin-2 in patients with advanced epithelial ovarian carcinoma. J Immunother Emphasis Tumor Immunol 19: 443-451, 1996.
37. De Waal Malefyt R and de Vries J: Direct effect of IL-10 on subsets of human CD4+ T-cell clones and resting T cells. Specific inhibition of IL-2 production and proliferation. J Immunol 150: 4754-4765, 1993.
38. Seo N, Hayakawa S, Takigawa M and Tokura Y: Interleukin-10 expressed at early tumor sites induces subsequent generation of CD4+ T-regulatory cells and systemic collapse of antitumor immunity. Immunology 103: 449-457, 2001.
39. Platsoucas CD, Fincke JE, Pappas J, Jung WJ, Heckel M, Schwarting R, Magira E, Monos D and Freedman RS: Immune responses to human tumors: development of tumor vaccines. Anticancer Res 23(3A): 1969-1996, 2003.
40. Pawelec G: Tumour escape: antitumour effectors too much of a good thing? Cancer Immunol Immunother 53: 262-274, 2004.
41. Hu MM, Urba WJ and Fox BA: Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile. J Immunol 15: 3033-3041, 1998.
42. Mocellin S, Ohnmacht GA, Wang E and Marincola FM: Kinetics of cytokine expression in melanoma metastases classifies immune responsiveness. Int J Cancer 93: 236-242, 2001.
43. Han X, Wilbanks GD, Devaja O, Ruperelia V and Raju KS: IL-2 enhances standard IFNgamma/LPS activation of macrophage cytotoxicity to human ovarian carcinoma in vitro: a potential for adoptive cellular immunotherapy. Gynecol Oncol 75: 198-210, 1999.
44. Nakamura Y, Ozaki T, Yanagawa H, Yasuoka S and Ogura T: Eosinophil colony-stimulating factor induced by administration of IL-2 into the pleural cavity of patients with malignant pleurisy. Am J Respir Cell. Mol Biol 3: 291-300, 1990.
45. Schaafsma MR, Falkenburg JH, Landegent JE, Duinkerken N, Osanto S, Ralph P, Kaushansky K, Wagemaker G, Van Damme J and Willemze R: In vivo production of IL-5, GM-CSF, M-CSF, and IL-6 during intravenous administration of high-dose IL-2 in cancer patients. Blood 78: 1981-1987, 1991.
46. Hamelmann E, Takeda K, Schwarze J, Vella AT, Irvin CG and Gelfand EW: Development of eosinophilic airway inflammation and airway hyperresponsiveness requires interleukin-5 but not immunoglobulin E or B lymphocytes. Am J Respir Cell Mol Biol 21: 480-489, 1999.
47. Tomaki M, Zhao LL, Lundahl J, Sjostrand M, Jordana M, Linden A, O'Byrne P and Lotvall J: Eosinophilopoiesis in a murine model of allergic airway eosinophilia: involvement of bone marrow IL-5 and IL-5 receptor alpha. J Immunol 165: 4040-4050, 2000.
48. Dobrzanski MJ, Reome JB and Dutton RW: Type 1 and type 2 CD8+ effector T cell subpopulations promote long-term tumor immunity and protection to progressively growing tumor. J Immunol 164: 916-925, 2000.
49. Dobrzanski MJ, Reome JB and Dutton RW: Role of effector cell-derived IL-4, IL-5, and perform in early and late stages of type 2 CD8 effector cell-mediated tumor rejection. J Immunol 167: 424-434, 2001.
50. Rivoltini L, Viggiano V, Spinazze S, Santoro A, Colombo MP, Takatsu K and Parmiani G: In vitro anti-tumor activity of eosinophils from cancer patients treated with subcutaneous administration of IL-2. Role of IL-5. Int J Cancer 54: 8-15, 1993.